Metabolomic profiling with NMR discriminates between biphosphonate and doxorubicin effects on B16 melanoma cells.
The metabolomic profiles of B16 melanoma cells were investigated in vitro with high resolution-magic angle spinning proton magnetic resonance spectroscopy and OPLS multivariate statistical analyse. We compared the profiles for untreated melanoma B16-F10 cells and Ca(2+) chelating EGTA, doxorubicin or BP7033 bisphosphonate treated cells. The two last molecules are known to induce anti-proliferative effects by different mechanisms of action in cells. Untreated and EGTA treated cells had similar profiles and were considered together as control cells. Several spectral regions could discriminate control from doxorubicin as well as BP7033 treated cells. Doxorubicin and BP7033 displayed distinct metabolic profiles. Important changes in neutral lipids and inositol were related to doxorubicin activity whereas BP7033 affected essentially phospholipids and alanine/lactate metabolism. These results provide new putative targets for both drugs. Metabolomics by NMR is shown here to be a good tool for the investigation of the mechanisms of action of drugs in pre-clinical studies.
Universités Paris 13 and Paris 6, Bobigny, France.
M N
MN
Triba
A
A
Starzec
N
N
Bouchemal
E
E
Guenin
G Y
GY
Perret
L
L
Le Moyec
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D004164:Diphosphonates / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D009682:Magnetic Resonance Spectroscopy / Q000379:methods*; D008546:Melanoma, Experimental / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D055442:Metabolome; D055432:Metabolomics / Q000379:methods*; D051379:Mice
D000903:Antibiotics, Antineoplastic; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004317:Doxorubicin